The best science for better lives The Lancet was founded in 1823 by Thomas Wakley and began as an independent, international weekly general medical journal. Since then, The Lancet has sought to address urgent topics, initiate debate, put science into context, and influence decision-makers worldwide. Evolving as a group of health and medical journals, we retain the belief that the best science must lead to better lives. Visit our website to learn more. publishing

Type: SMB Activities: healthtech deeptech biotech

The European Moonshot Factory The Joint European Disruptive Initiative (JEDI) is the initiative for disruptive innovation to bring Europe in a leadership position in breakthrough technologies. It is powered by 4.600 leaders of Europe’s deeptech ecosystem in 29 countries. JEDI is launching Technology GrandChallenges to push the frontiers of innovation, with a radical new method based on excellence, no geographical return, speed, highest expectations & bold risk-taking. Driven by European values, a purpose-driven approach to solve major societal issues in environment/healthcare/digital/education/oceans/space through innovation. Europe needs a revolution to stay in the race, defend its values, and lead Follow us on …

Type: NGO, Think-tanks, Ed, & Culture Activities: it services

Conquering cancer through research, education, and promotion of the highest quality, equitable patient care. Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality and equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO’s Conquer Cancer Foundation supports the Society by funding groundbreaking research …

Type: NGO, Think-tanks, Ed, & Culture Activities: healthtech

Redefining the future of drug development with a non-conventional biopharmaceutical model Landmark BioVentures AG (LBV), founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart resource allocation and a diversified yet complementary pipeline of 10 first-in-class therapeutics, each being developed within a nexus of seven startups built from the ground up. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments to streamline drug …

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology